Company Insights

AQST customer relationships

Explore interactive graphBrowse insights index

AQST customers relationship map

Aquestive Therapeutics (AQST): the commercial-manufacturer at the center of oral thin‑film partnerships

Aquestive monetizes by licensing its proprietary oral thin‑film formulations to established pharma partners and acting as the exclusive commercial manufacturer for those licensees; revenue mixes include manufacture-and-supply fees, license/royalty receipts and milestone or development service fees. The company is a manufacturing-led specialty pharma with outsized revenue concentration in a single partner (Indivior) while maintaining a portfolio of license relationships that generate recurring supply revenue worldwide. For a quick orientation, visit the firm homepage at https://nullexposure.com/.

How Aquestive’s business model actually works for investors

Aquestive operates as a hybrid contractor and licensor: it develops film technology, grants commercialization rights to partners, and retains exclusive manufacturing responsibility for those partnered products. That structure drives three investment characteristics: high customer concentration and counterparty dependence, predictable manufacturing revenue streams from licensed products, and operational leverage from facility capacity that supports third‑party supply agreements. The company reports manufacturing and supply as the largest revenue component, complemented by license and royalty income plus occasional development milestones (AQST 10‑K, FY2024).

Relationship map — every counterparty flagged in the sources

Below are the customer relationships disclosed across AQST filings and press coverage, each summarized succinctly with source attribution.

Kaleo, Inc.

Aquestive references Kaleo in the context of autoinjector competitors in the epinephrine market; Kaleo markets Auvi‑Q which is mentioned as a standard‑of‑care device alternative in the 10‑K discussion of market landscape (AQST 10‑K, FY2024).

Assertio Holdings, Inc. (and subsidiary Otter Pharmaceuticals / ASRT)

Aquestive licensed Sympazan (clobazam) to Otter Pharmaceuticals, a subsidiary of Assertio, and has a long‑term supply arrangement under which Aquestive is the exclusive worldwide manufacturer and supplier for Sympazan, generating manufacturing fees under that agreement (AQST 10‑K, FY2024; GlobeNewswire press release, Mar 4, 2026).

Otter Pharmaceuticals

Otter is the Assertio subsidiary that holds the licensed Sympazan relationship; Aquestive granted an exclusive worldwide license for Sympazan to Otter and continues as the product’s manufacturer (AQST 10‑K, FY2024; GlobeNewswire, Mar 4, 2026).

Zambon S.p.A. (Zambon)

Aquestive granted Zambon a license to develop and commercialize Exservan (riluzole oral film) in Europe, where Zambon commercializes the product as Emylif; press filings and investor materials also cite an Emylif collaboration (AQST 10‑K, FY2019 disclosure cited in FY2024 10‑K; StockTitan 8‑K summarizing 2026 material event).

Sunovion Pharmaceuticals Inc.

Sunovion is noted as the commercial launcher of KYNMOBI (apomorphine) after FDA approval in 2020; AQST’s 10‑K references Sunovion’s commercial activities in the context of partners and launched products (AQST 10‑K, FY2024).

Indivior Inc. (INDV)

Indivior is the single largest counterparty for Aquestive’s revenues: Indivior holds global commercialization rights to Suboxone and Aquestive is the exclusive manufacturer of Suboxone film, with Indivior contributing the majority share of AQST revenue historically (AQST 10‑K, FY2024; INDV 10‑K, FY2024; GlobeNewswire and StockTitan 2026 releases confirming ongoing manufacturing).

INDV (stock/ticker references)

Market and press items list Indivior under the ticker INDV when reporting that Suboxone film is manufactured under an exclusive license and supply agreement with Aquestive; the company’s SEC filings reiterate that exclusivity (INDV 10‑K, FY2024; AQST investor releases, 2026).

ASRT (ticker)

News outlets reference Assertio with ticker ASRT when describing the Sympazan film relationship and the transfer of film formulation rights to Assertio as part of Aquestive’s monetization of that asset (GlobeNewswire, Mar 4, 2026; FiercePharma coverage, 2026).

Hypera Pharma / Hypera‑Pharma (HYPE3 / HYPMY)

Aquestive licensed commercial rights for Ondif (ondansetron oral film) to Hypera for Brazil, and press releases and AQST product lists reference Hypera as a commercial partner marketing Ondif in Brazil (AQST 10‑K, FY2024; GlobeNewswire and StockTitan 2026 notices).

HYPE3 / HYPMY (ticker variants)

Investor materials and market reporting cite Hypera under local ticker notations (HYPE3, HYPMY) in Brazil when describing the Ondif collaboration; these symbol references appear in press summaries of AQST’s partner portfolio (GlobeNewswire, Mar 4, 2026; AQST 10‑K context).

Otter Pharmaceuticals (news citation duplicate)

Separately called out in recent investor updates and press filings as the licensee for Sympazan, Otter’s role is reiterated in AQST investor communications (GlobeNewswire, Mar 4, 2026; StockTitan 8‑K).

(Note: several results are duplicates or ticker aliases of the same partner — the list above consolidates those while acknowledging the ticker/name variants reported in filings and press.)

Operational constraints and what they imply for risk and upside

Aquestive’s public disclosures establish a set of structural constraints that shape investor risk/reward.

  • Customer concentration and criticality: Indivior accounted for roughly 62% of revenue in 2024 and ~80% in 2023, a material dependence that creates earnings volatility tied to a single partner’s demand and contract renewal profile (AQST 10‑K, FY2024). This is a relationship‑level signal linked directly to Indivior’s role as the principal buyer and licensee.

  • Contracting posture is mixed: AQST documents both long‑term supply agreements (explicitly with Assertio for Sympazan, where AQST is the exclusive manufacturer) and other arrangements that reflect shorter operational cycles. The Assertio excerpt explicitly confirms a long‑term exclusive manufacturing and supply commitment (AQST 10‑K, FY2024).

  • Manufacturing as the core operational segment: AQST reports manufacturing and supply as the largest revenue line and positions itself as the exclusive manufacturer for its licensed products, which yields recurring production fees but also ties capital intensity and capacity utilization to partner demand (AQST 10‑K, FY2024).

  • Geographic reach is global with U.S. concentration: Revenues are reported by region with the U.S. as the dominant market, but licensed products are marketed globally through licensees, creating global commercialization upside but also geographic execution risk via partner performance (AQST 10‑K, FY2024).

  • Relationship maturity and stage: The Suboxone manufacturing relationship is mature and high‑volume (over 2.7 billion doses produced since launch), while other partnerships (Sympazan, Emylif, Ondif) are active commercial programs at various stages of lifecycle and market penetration (AQST disclosures).

  • Business model constraints as company signals: Short‑term interactions (employee ESPP) and individual counterparty elements are present, but the dominant signals for investors are concentration, exclusivity of manufacturing rights, and global licensing distribution rather than spot commercial sales.

What investors should watch next

  • Monitor renewal or re‑pricing activity with Indivior and the pace of demand for Suboxone film; given Indivior’s revenue share, any adverse change will materially affect AQST top line.
  • Track manufacturing volume ramps for Sympazan (Assertio/Otter) and Ondif (Hypera) as evidence of diversification away from a single large partner.
  • Assess capacity utilization and capital expenditure guidance — the model’s upside depends on converting facility capacity into contracted supply agreements.

For deeper company relationship intelligence and timely filings, review the company materials and recent investor updates at https://nullexposure.com/.

Bold takeaway: Aquestive is a manufacturing‑first specialty pharma whose valuation is driven less by proprietary commercial success and more by the stability and scale of a small number of long‑term license and supply partnerships. Investors should underwrite that concentration and the exclusivity of manufacturing obligations when modeling cash flow and downside risk.

Join our Discord